ELTP news

Elite Pharmaceuticals announced the U.S. commercial launch of its generic Requip XL tablets, a non-ergoline dopamine agonist used to treat Parkinson's disease. The product offers a competitive entry into a market with $10 million in annual branded sales.

Elite Pharmaceuticals reported consolidated revenues of $148.9 million, representing a 77% increase driven by key product launches. This significant operational improvement highlights the company's successful expansion in generic pharmaceuticals.

Elite Pharmaceuticals announced it will release its fiscal year 2026 financial results on Monday, June 29. Market participants will receive further details during a live conference call and question session on Tuesday, June 30.

Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug, with the generic product demonstrated as bioequivalent to the branded product. The company plans to file an Abbreviated New Drug Application with the FDA, potentially …

Elite Pharmaceuticals submitted an Abbreviated New Drug Application to the FDA for a generic anticoagulant product in a $26 billion market with no current generic competition. Approval depends on FDA clearance and addressing unexpired patents and exclusivities of the branded product.